Molecular biology of Barrett's cancer

Best Practice and Research: Clinical Gastroenterology

Volumn 20, Issue 5, 2006, Pages 813-827

  Atherfold, Paul A ^b   Jankowski, Janusz A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

Barrett's adenocarcinoma; Barrett's metaplasia; bile acids; chronic inflammation; clonal expansion; gastrin; molecular changes; stem cell biology

Indexed keywords

ACETYLSALICYLIC ACID; APC PROTEIN; BILE ACID; CHENODEOXYCHOLIC ACID; CYCLIN D1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DEOXYCHOLIC ACID; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GASTRIN; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; NITRATE; PROSTAGLANDIN E2; PROTEIN P16; PROTEIN P53; PROTON PUMP INHIBITOR; PYRUVATE KINASE; TRANSCRIPTION FACTOR CDX2; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CELL PROLIFERATION; DIETARY INTAKE; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; GASTRITIS; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEREDITY; HUMAN; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; BILE ACIDS AND SALTS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; GASTRINS; GASTROESOPHAGEAL REFLUX; HUMANS; INFLAMMATION MEDIATORS; METAPLASIA; PREVALENCE;

EID: 33748692000     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2006.04.003     Document Type: Article

References (96)

1. Pera M., Cameron A.J., Trastek V.F., et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104 2 (1993) 510-513
2. Tytgat G.N.J. Does endoscopic surveillance in esophageal columnar metaplasia (Barretts-Esophagus) have any real value. Endoscopy 27 1 (1995) 19-26
3. Pera M., Manterola C., Vidal O., et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol 92 3 (2005) 151-159
4. Vonzeyne E.R. Survey of cancer of esophagus in relation to other malignant neoplasms. S Afr Med J 47 8 (1973) 325-331
5. Noffsinger A. Neoplastic risk assessment in Barrett's esophagus: how far have we come?. Hum Pathol 34 10 (2003) 965-967
6. Weinstein W.M., and Ippoliti A.F. The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc 44 1 (1996) 91-95
7. Jankowski J. Gene-expression in Barretts mucosa - acute and chronic adaptive responses in the esophagus. Gut 34 12 (1993) 1649-1650
8. Jankowski J.A., Provenzale D., and Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 122 2 (2002) 588-590
9. Iijima K., Henry E., Moriya A., et al. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology 122 5 (2002) 1248-1257
10. Moriya A., Grant J., Mowat C., et al. In vitro studies indicate that acid catalysed generation of N-nitrosocompounds from dietary nitrate will be maximal at the gastro-oesophageal junction and cardia. Scand J Gastroenterol 37 3 (2002) 253-261
11. Mowat C., Williams C., Gillen D., et al. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology 119 2 (2000) 339-347
12. Poynton A.R., Walsh T.N., O Sullivan G., et al. Carcinoma arising in familial Barrett's esophagus. Am J Gastroenterol 91 9 (1996) 1855-1856
13. Fass R., Sampliner R.E., and Spechler S.J. The relationship between esophageal acid exposure, dysplasia and extent of columnar metaplasia in Barrett's esophagus. Gastroenterology 118 4 (2000) A685
14. Fass R., Hell R.W., Garewal H.S., et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 48 3 (2001) 310-313
15. Winters C., Spurling T.J., and Chobanian S.J. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92 (1987) 118-124
16. Souza R.F., Morales C.P., and Spechler S.J. Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment Pharmacol Ther 15 8 (2001) 1087-1100
17. Barrett M.T., Sanchez C.A., Prevo L.J., et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22 1 (1999) 106-109
18. Vieth M., Masoud B., Meining A., et al. Helicobacter pylori infection: protection against Barrett's mucosa and neoplasia?. Digestion 62 4 (2000) 225-231
19. Lord R.V.N., Brabender J., Wickramasinghe K., et al. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 138 5 (2005) 924-931
20. Montgomery R.K., Mulberg A.E., and Grand R.J. Development of the human gastrointestinal tract: twenty years of progress. Gastroenterology 116 3 (1999) 702-731
21. Silberg D.G., Sullivan J., Kang E., et al. Cdx2 ectopic expression induced gastric intestinal metaplasia in transgenic mice. Gastroenterology 122 3 (2002) 689-696
22. Moons L.M.G., Bax D.A., Kuipers E.J., et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 57 10 (2004) 1063-1068
23. Wong N.A.C.S., Wilding J., Bartlett S., et al. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci U S A 102 21 (2005) 7565-7570
24. Jenkins G.J.S., Doak S.H., Parry J.M., et al. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 89 7 (2002) 824-837
25. Jankowski J., Austin W., Howat K., et al. Proliferating cell nuclear antigen in esophageal mucosa - comparison with autoradiography. Eur J Gastroenterol Hepatol 4 7 (1992) 579-584
26. Sodhani P., Gupta S., Prakash S., et al. Columnar and metaplastic cells in vault smears: cytologic and colposcopic study. Cytopathology 10 2 (1999) 122-126
27. Arnold I., and Watt F.M. c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 11 8 (2001) 558-568
28. Fass R., and Sampliner R.E. Extension of squamous epithelium into the proximal stomach: a newly recognized mucosal abnormality. Endoscopy 32 1 (2000) 27-32
29. Wallner B., Sylvan A., Stenling R., et al. The esophageal Z-line appearance correlates to the prevalence of intestinal metaplasia. Scand J Gastroenterol 35 1 (2000) 17-22
30. Conio M., Lapertosa G., Blanchi S., et al. Barrett's esophagus: an update. Crit Rev Oncol Hematol 46 2 (2003) 187-206
31. Morales C.P., Souza R.F., and Spechler S.J. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 360 9345 (2002) 1587-1589
32. Spechler S.J. Barrett's esophagus. N Engl J Med 346 11 (2002) 836-842
33. Sarosi G., Brown G., Jaiswal K., et al. Reflux-damaged esophageal epithelium is replaced by cells derived from the bone marrow in a rat model of Barrett's esophagus. Gastroenterology 126 2 (2004 April) A35
34. Sidransky D., Frost P., Voneschenbach A., et al. Clonal origin of bladder-cancer. N Engl J Med 326 11 (1992) 737-740
35. Schmidt P.H., Lee J.R., Joshi V., et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 79 6 (1999) 639-646
36. Greaves L.C., Preston S.L., Tadrous P.J., et al. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc Natl Acad Sci U S A 103 3 (2006) 714-719
37. Booth C., and Potten C.S. Gut instincts: thoughts on intestinal epithelial stem cells. J Clin Invest 105 11 (2000) 1493-1499
38. Jankowski J.A., Harrison R.F., Perry I., et al. Barrett's metaplasia. Lancet 356 9247 (2000) 2079-2085
39. Montgomery E., Goldblum J.R., Greenson J.K., et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32 4 (2001) 379-388
40. Schnell T.G., Sontag S.J., Chejfec G., et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120 7 (2001) 1607-1619
41. Weston A.P., Sharma P., Topalovski M., et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 95 8 (2000) 1888-1893
42. Buttar N.S., Wang K.K., Sebo T.J., et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120 7 (2001) 1630-1639
43. Reid B.J., Levine D.S., Longton G., et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95 7 (2000) 1669-1676
44. Robert V., Michel P., Flaman J.M., et al. High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis. Carcinogenesis 21 4 (2000) 563-565
45. Rice T.W., Goldblum J.R., Falk G.W., et al. P53 immunoreactivity in Barretts metaplasia, dysplasia, and carcinoma. J Thorac Cardiovasc Surg 108 6 (1994) 1132-1137
46. Younes M., Lebovitz R.M., Lechago L.V., et al. P53 protein accumulation in Barretts metaplasia, dysplasia, and carcinoma - a follow-up-study. Gastroenterology 105 6 (1993) 1637-1642
47. Galipeau P.C., Prevo L.J., Sanchez C.A., et al. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 91 24 (1999) 2087-2095
48. Wijnhoven B.P.L., Tilanus H.W., and Dinjens W.N.M. Molecular biology of Barrett's adenocarcinoma. Ann Surg 233 3 (2001) 322-337
49. Coppola D., Falcone R., Livingston S., et al. Cyclin D1 expression correlates with degrees of dysplasia in Barrett's esophagus. Lab Invest 76 1 (1997) 298
50. Klump B., Hsieh C.J., Holzmann K., et al. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 115 6 (1998) 1381-1386
51. Singh A.B., and Harris R.C. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 17 10 (2005) 1183-1193
52. Fitzgerald R.C., and Triadafilopoulos G. Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis 16 2 (1998) 63-80
53. Vissers K.J., Riegman P.H.J., Alers J.C., et al. Involvement of cancer-activating genes on chromosomes 7 and 8 in esophageal (Barrett's) and gastric cardia adenocarcinoma. Anticancer Res 21 6A (2001) 3813-3820
54. Wilkinson N.W., Black J.D., Roukhadze E., et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 8 4 (2004) 448-453
55. Gibson M.K., Abraham S.C., Wu T.T., et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 9 17 (2003) 6461-6468
56. Herrera L.J., El-Hefnawy T., de Oliveira P.E.Q., et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 7 1 (2005) 75-84
57. Anderson M.R., Campbell M., and Jankowski J.A.Z. HGF/MET induces downregulation of E-cadherin and increases TCF/beta-catenin signaling in oesophageal adenocarcinoma. Gut 52 (2003) A31-A32
58. Auvinen M.I., Sihvo E.I.T., Ruohtula T., et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 20 13 (2002) 2971-2979
59. Bailey T., Biddlestone L., Shepherd N., et al. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence - correlation with disease progression and dedifferentiation. Am J Pathol 152 1 (1998) 135-144
60. Eigenbrodt E., Basenau D., Holthusen S., et al. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 17 4B (1997) 3153-3156
61. Koss K., Harrison R.F., Gregory J., et al. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. J Clin Pathol 57 11 (2004) 1156-1159
62. Wetscher G.J., Profanter C., Gadenstatter M., et al. Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility. Langenbecks Arch Chir 382 2 (1997) 95-99
63. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 11 (1999) 825-831
64. Triadafilopoulos G. Proton pump inhibitors for Barrett's oesophagus. Gut 46 2 (2000) 144-146
65. Watson S.A., and Smith A.M. Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis. Cancer Res 61 2 (2001) 625-631
66. Wetscher G.J., Hinder R.A., Smyrk T., et al. Gastric acid blockade with omeprazole promotes gastric carcinogenesis induced by duodenogastric reflux. Dig Dis Sci 44 6 (1999) 1132-1135
67. Tselepis C., Morris C.D., Wakelin D., et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 52 2 (2003) 174-180
68. Raj A., and Jankowski J. Acid suppression and chemoprevention in Barrett's oesophagus. Dig Dis 22 2 (2004) 171-180
69. Stamp D. Bile acids and esophageal cancer. Gastroenterology 124 1 (2003) 271-272
70. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 9255 (2001) 539-545
71. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 6917 (2002) 860-867
72. Sung J.J.Y., Lin S.R., Ching J.Y.L., et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 119 1 (2000) 7-14
73. Polkowski W., van Lanschot J.J.B., ten Kate F.J.W., et al. Intestinal and pancreatic metaplasia at the esophagogastric junction in patients without Barrett's esophagus. Am J Gastroenterol 95 3 (2000) 617-625
74. Di Sebastiano P., di Mola F.F., Di Febbo C., et al. Expression of interleukin 8 (IL-8) and substance P in human chronic pancreatitis. Gut 47 3 (2000) 423-428
75. Lu L., and Haber M. Pancreatic metaplasia in different disease states and the association with inflammation. Lab Invest 76 1 (1997) 336
76. Schouten W.R. Pouchitis. Mediators Inflamm 7 3 (1998) 175-181
77. Dixon M.F. Patterns of inflammation linked to ulcer disease. Best Pract Res Clin Gastroenterol 14 1 (2000) 27-40
78. Vujanic G.M., and Dojcinov S.D. Diversion colitis in children: an iatrogenic appendix vermiformis?. Histopathology 36 1 (2000) 41-46
79. Takeda H., Nagashima R., and Goto T. Endoscopic observation of squamous metaplasia of the stomach: a report of two cases. Endoscopy 32 8 (2000) 651-653
80. Higaki S., Akazawa A., and Nakamura H. Metaplastic polyp of the colon develops in response to inflammation. J Gastroenterol Hepatol 14 7 (1999) 709-714
81. Voutilainen M., Farkkila M., Juhola M., et al. Complete and incomplete intestinal metaplasia at the oesophagogastric junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis. Gut 45 5 (1999) 644-648
82. O'Riordan J.M., bdel-latif M.M., Ravi N., et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 100 6 (2005) 1257-1264
83. Tselepis C., Perry I., Dawson C., et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 21 39 (2002) 6071-6081
84. Naya M.J., Pereboom D., Ortego J., et al. Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits. Gut 40 2 (1997) 175-181
85. Kabe Y., Ando K., Hirao S., et al. Redox regulation of NF-kappa B activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 7 3-4 (2005) 395-403
86. Yamamoto K., Arakawa T., Ueda N., et al. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270 52 (1995) 31315-31320
87. Ottonello L., Gonella R., Dapino P., et al. Prostaglandin E-2 inhibits apoptosis in human neutrophilic polymorphonuclear leukocytes: role of intracellular cyclic AMP levels. Exp Hematol 26 9 (1998) 895-902
88. Leppert D., Hauser S.L., Kishiyama J.L., et al. Stimulation of matrix metalloproteinase-dependent migration of T-cells by eicosanoids. FASEB J 9 14 (1995) 1473-1481
89. Mulholland G., Ardill J.E.S., Fillmore D., et al. Helicobacter pylori related hypergastrinemia is the result of a selective increase in gastrin-17. Gut 34 6 (1993) 757-761
90. Aly A., Shulkes A., and Baldwin G.S. Gastrins, cholecystokinins and gastrointestinal cancer. Biochim Biophys Acta 1704 1 (2004) 1-10
91. Haigh C.R., Attwood S.E.A., Thompson D.G., et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 124 3 (2003) 615-625
92. Varro A., Noble P.J., Wroblewski L.E., et al. Gastrin-cholecystokinin(B) receptor expression in AGS cells is associated with direct inhibition and indirect stimulation of cell proliferation via paracrine activation of the epidermal growth factor receptor. Gut 50 6 (2002) 827-833
93. Harris J.C., Clarke P.A., Awan A., et al. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 64 6 (2004) 1915-1919
94. Feurle G.E., Helmstaedter V., Buehring A., et al. Distinct immunohistochemical findings in columnar epithelium of esophageal inlet patch and of Barrett esophagus. Dig Dis Sci 35 1 (1990) 86-92
95. Griffin M., and Sweeney E.C. The relationship of endocrine-cells, dysplasia and carcinoembryonic antigen in Barrett mucosa to adenocarcinoma of the esophagus. Histopathology 11 1 (1987) 53-62
96. Hagen J.A., DeMeester S.R., Peters J.H., et al. Curative resection for esophageal adenocarcinoma - analysis of 100 en bloc esophagectomies. Ann Surg 234 4 (2001) 520-530